Biopharma Adapts to Access and Affordability Landscape

Here's a snippet from a great conversation I had with Miranda Delatore DNP, RN, NEA-BC and Megan Wetzel at #Asembia AXS26! Check out the full interview here: https://lnkd.in/ejxA4Kz6

What's in store for pharma in the next few years? Here's what Miranda Delatore DNP, RN, NEA-BC at CoverMyMeds has to say... For more exclusive industry insights 👉 https://lnkd.in/exX8pVS3 #Pharma #PatientAccess #SpecialtyPharma #Biopharma

Always glad and inspired to talk patient access. At Cencora, we are united by our mission to create healthier futures, and real-world evidence (RWE) is a powerful way to help maximize patient benefit worldwide. When done well, RWE strengthens decision-making for stakeholders across the healthcare ecosystem, helping ensure innovation reaches patients as quickly as possible.

Where does real world evidence have the greatest impact in the specialty pharma pipeline? Here's what Cencora's Tommy Bramley has to say about it. 👉 Check out more exclusive #Asembia AXS26 coverage, live from Las Vegas: https://lnkd.in/egU8rzM5 #Pharma #SpecialtyPharma #RWE #Biopharma

At #Asembia AXS26 in Las Vegas, we asked industry leaders what they "bet" will shape pharma over the next few years. 👉 Here's what Kim Plesnarski of Syneos Health Commercial Solutions had to say about it. 🎬  Watch the first part of Plesnarski's interview, live from Asembia: https://lnkd.in/dbvJ89_G #pharma #specialtypharma #biopharma #lifesciences

Our CEO, William Shrank, sat down with Stephen Appezzato at #Asembia AXS26 to discuss where specialty pharmacy stands and how stakeholders across the industry must come together to unlock the full potential of today's existing transformative therapies. Watch the full interview below:

Bicara Therapeutics Q1 GAAP EPS -$0.93 Misses: Bicara reported GAAP EPS of -$0.93 vs consensus -$0.65 on May 11, 2026; the $0.28 shortfall raises funding and milestone risk for this clinical-stage biote http://dlvr.it/TSTZq4 👈 Read full analysis #BicaraTherapeutics #Biotech #EarningsReport #GAAPEPS #Pharmaceuticals

Here's an interesting example in which real-world evidence was generated for a biosimilar to demonstrate its value in clinical practice as well as to provide greater confidence to stakeholders in the face of upcoming competition. If you're working on biosimilars, what has been your approach to communicating the value of a product supposedly the same as the original version? #HEOR #ACCESS #PHARMA

📈 Initiating Coverage with Bullish Outlook NRx Pharmaceuticals, Inc. (NRXP) is highlighted for its role in transitioning the ketamine market from off-label use to standardized care. Coverage has been initiated with a Buy rating and $49 price target, reflecting strong expectations for the company’s clinical and commercialization strategy. READ HERE👇🏻 https://lnkd.in/eE6HtSyn 👉🏻Learn more at https://lnkd.in/eHTFidU7 Watch the New to The Street interview here👇🏻 https://lnkd.in/gQ7KiBYX #NRX #pharma #healthcare #biotechnews #innovation #businessupdate #businessnews #business #news #newtothestreet 

56% of patients who are prescribed a new branded medication never initiate therapy. For the first time, pharma manufacturers can take complete control of how their molecule meets the market. BlinkRx removes every barrier between your brand and your patients. https://bit.ly/3ZBf8bn #Asembia26 #PrescriptionJourney #Pharma #PatientAccess